|
|
|
|
Better Patient Outcomes Observed With Drug Eluting Stents 1 Year After Angioplasty
-- Patients receiving drug eluting stents (DES) as part of an angioplasty had better outcomes 1 year later than patients with bare metal stents (BMS), according to a study published early online and appearing in the January 2009 issue of the...
|
|
|
Coated Stents Better Than Bare Metal Ones in Short Run
THURSDAY, Dec.18 (HealthDay News) -- Angioplasty patients who receive stents coated with medication to prevent narrowing of the artery do better one year after the surgery than those who receive bare metal stents, a new study shows....
|
|
|
ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
PLYMOUTH, Minn., Dec.9 /PRNewswire-FirstCall/ -- ev3 Inc. , a global endovascular device company, announced today that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market its EverCross 0...
|
|
|
ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
PLYMOUTH, Minn., Dec.9 /PRNewswire-FirstCall/ -- ev3 Inc. , a global endovascular device company, announced today that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market its EverCross 0.035'...
|
|
|
ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
PLYMOUTH, Minn., Dec.9 /PRNewswire-FirstCall/ -- ev3 Inc. , a global endovascular device company, announced today that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market its EverCross 0...
|
|
|
ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
PLYMOUTH, Minn., Dec.9 /PRNewswire-FirstCall/ -- ev3 Inc. , a global endovascular device company, announced today that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market its EverCross 0...
|
|
|
Medtronic Launches Sprinter Angioplasty Balloon Cathethers on Rapid Exchange
Expanding its angioplasty product portfolio, Medtronic, Inc., announced the U.S.Medtronic Launches Sprinter Angioplasty Balloon Cathethers on Rapid Exchange.
|
|
|
Good Long-Term Results Seen With Balloon Angioplasty for Aortic Coarctation
_ Good Long-Term Results Seen With Balloon Angioplasty for Aortic Coarctation.
|
|
|
Medtronic Launches Sprinter(R) Angioplasty Balloon Cathethers On Rapid Exchange
Expanding its angioplasty product portfolio, (NYSE: MDT), announced today the U.S.market launch of the Sprinter Legend (semicompliant) and the NC Sprinter (noncompliant) balloon dilatation catheters on a rapid exchange delivery system.
|
|
|
Angioplasty reduces long-term cardiac risk among heart patients with 'silent' ischemia
When compared with intensive drug therapy, percutaneous coronary intervention (PCI, angioplasty) was more beneficial in reducing the long-term risk of major cardiac events among heart attack survivors with silent ischemia.When compared...
|
|
|
Medtronic Launches Sprinter Angioplasty Balloon Cathethers on Rapid Exchange
- Expanding its angioplasty product portfolio, Medtronic, Inc.(NYSE: MDT), announced today the U.S. market launch of the Sprinter Legend (semicompliant) and the NC Sprinter (noncompliant) balloon dilatation catheters on a rapid exchange...
|
